Screener
EBITDA at other companies
Other financials
Where this comes from
Calculated from Kiniksa Pharmaceuticals International, plc’s reported figures.
The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026. Open the filing →
- Filed
- Jul 28, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-087545
FAQ
- What is Kiniksa Pharmaceuticals International, plc's EBITDA?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported EBITDA of $27.67M in Q2 2026.
- How has Kiniksa Pharmaceuticals International, plc's EBITDA changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's EBITDA increased by 34.8% year-over-year, from $20.52M to $27.67M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's EBITDA?
- Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's EBITDA has grown at a -15.5% compound annual growth rate (CAGR), from -$154.28M to $78.78M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Kiniksa Pharmaceuticals International, plc's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude